Equillium, Inc. EQ
Set alert
1.37 USD -0.05 -3.52%
At close · Oct 30
1.37 0.00 0.00%
After hours · Oct 30, 6:42 PM ET
1.29 Day range 1.42
0.84 52-week range 3.20
- YTD
- -11.61%
- 1 year
- -3.52%
- Open
- 1.38
- Prev close
- 1.42
- Mkt cap
- 107.36M
- Vol
- 310.72K
- Avg vol
- 581.01K
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.29
- High
- 1.42
- Forward P/E
- -0.47
- Beta
- 1.83
- Short ratio
- 0.53
- Inst. own
- 20.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.8356
- 200-d avg
- 1.15
- 1y target
- 3.33
2Y chart
Events in this range
- Nov 1, 2024Downgrade: Jones Trading · Buy → Hold
- Nov 13, 2024Earnings: 0; estimate 0.07; surprise —%
Signals (82)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 22, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| RSI: Overbought | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bearish | Apr 8, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| RSI: Overbought | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Feb 18, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 27, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 21, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 28, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| RSI: Oversold | Nov 13, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| RSI: Overbought | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| RSI: Overbought | Sep 3, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| RSI: Overbought | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| RSI: Oversold | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 14, 2025 | 1 year ago |
| SMA: Bullish | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 6, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| RSI: Overbought | Feb 6, 2025 | 1 year ago |
| SMA: Bullish | Feb 5, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 21.19M
- Enterprise value
- -8.45M
- Trailing P/E
- 0.00
- Forward P/E
- -0.47
- PEG ratio
- 0.00
- Price / sales
- 0.50
- Price / book
- 0.93
- EPS (TTM)
- -0.12
- Beta
- 1.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -19.51%
- Revenue (TTM)
- 42.62M
- Revenue growth
- 51.80%
- Free cash flow
- -6.72M
- Total cash
- 33.30M
- Total debt
- 609.00K
- Return on equity
- -33.67%
- Shares outstanding
- 35.43M
- Short % of float
- 0.54%
- 50-day average
- 0.8356
- 200-day average
- 1.15
Analyst view
Consensus: none
Price target (mean) 3.33 +143.3% upside
Now 1.37
- Target (low)
- 2.00
- Target (mean)
- 3.33
- Target (high)
- 5.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.26.
Financials — quick view
EQ Revenue — quarterly 0
EQ Net income — quarterly -4.69M
EQ EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.07 | 0.00 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.15 | 0.01 | +0.16 | +106.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.15 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.17 | -0.08 | +0.09 | +52.94% |
| May 9, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| Mar 25, 2024 | Dec 1, 2023 | -0.17 | -0.07 | +0.10 | +58.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Jones Trading | down | Buy | Hold |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 26, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- equilliumbio.com
News
- Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases
- Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
- Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
- Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
- Equillium Announces Poster Presentations at the 7th International AHR Conference
- Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
- Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
- Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
Your note
Sign in to keep a note on EQ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KEYES JASON A | Chief Financial Officer | Sale | Nov 13, 2024 | 0 |
| ROTHMAN JOEL | Officer | Stock Award(Grant) | Dec 7, 2023 | 58,150 |
| TOM PENNY | Officer | Sale | Oct 27, 2024 | 6,533 |
| ZEDELMAYER CHRISTINE | Chief Operating Officer | Sale | Oct 27, 2024 | 135,246 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Decheng Capital LLC | 12.55% | 4,447,308 | 2.66M | Sep 29, 2024 |
| Vanguard Group Inc | 2.38% | 841,948 | 503.48K | Sep 29, 2024 |
| Cota Capital Management, Llc | 1.59% | 562,278 | 336.24K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.91% | 321,173 | 192.06K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.58% | 204,385 | 122.22K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 0.31% | 108,691 | 65.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.61% | 570,835 | 341.36K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.70% | 247,430 | 147.96K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.29% | 104,381 | 62.42K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 35,240 | 21.07K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.10% | 33,945 | 20.30K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 24,554 | 14.68K | Oct 30, 2024 |